Amryt's Mycapssa Gets Orphan Drug Status For Treatment Of Carcinoid Syndrome

Amryt (AMYT) on Thursday said the Food and Drug Administration has granted Orphan Drug Designation to its Mycapssa for the treatment of carcinoid syndrome.

Carcinoid syndrome is a set of symptoms associated with neuroendocrine tumors (NETs).

Mycapssa (oral octreotide) is approved by the FDA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated injectable treatment with octreotide or lanreotide.

Pharmacokinetic studies with Mycapssa showed dose linearity from 20mg to 80mg, hence support dosing requirements for the planned Phase 3 study in patients with carcinoid syndrome, planned to be initiated early in 2023, Amryt said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Omnichannel retailer Macy's, Inc. announced Monday plans to hire colleagues for more than 41,000 full- and part-time seasonal positions for the upcoming holiday season. The colleagues will be positioned at its Macy's, Bloomingdale's and Bluemercury stores, supply chain locations and call centers. Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go. Lyft announced the expansion to its partnership with Indeed in Jobs Access program. The ride-hailing company will be providing transportation access for Indeed's Ready to Work program. Indeed's Ready to Work program is a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 15 to October 8, 2022.
Follow RTT